According to our (Global Info Research) latest study, the global Europium Nanoparticle for Rapid Diagnosis market size was valued at US$ 6.03 million in 2025 and is forecast to a readjusted size of US$ 11.96 million by 2032 with a CAGR of 8.8% during review period.
In 2025, the global production of Europium Nanoparticles for Rapid Diagnosis reached approximately 18.6 tons, with an average selling price of approximately US$315,000 per ton, production capacity of approximately 25.8 tons, and a gross margin of approximately 47.5%.
Europium (Eu), a rare earth element, has been widely explored for its applications in biological immunofluorescence diagnosis due to its unique luminescent properties. Here is an overview of why and how it's used:
Long Fluorescence Lifetimes: Europium complexes have fluorescence lifetimes of microseconds to milliseconds, which are significantly longer than conventional organic fluorophores. This time gap allows researchers to perform time-gated detection, reducing autofluorescence from biomolecules and background noise, thus improving the sensitivity and accuracy of assays.
High Stability: Europium chelates or cryptates are highly stable, providing consistent fluorescence signals that don't photobleach. The stability of these fluorescent compounds ensures the reliability of diagnostic tests over extended periods.
Sharp Emission Spectra: Europium complexes exhibit sharp emission spectral peaks, which enables multiplexing, meaning several different probes can be detected simultaneously without overlap. This is particularly useful in high-throughput screening or when it's necessary to detect multiple targets at once.
In terms of application in biological immunofluorescence diagnosis, europium-labeled immunoassays are commonly used. These techniques involve creating a complex between europium and an antibody specific to the target antigen. When the antigen is present, the europium-labelled antibody binds to it. The resulting complex can then be detected through the characteristic fluorescence of europium, allowing accurate identification and quantification of the target antigen.
Overall, the use of europium in biological immunofluorescence diagnostics continues to be a promising field, potentially contributing to the development of more accurate, sensitive, and high-throughput diagnostic methods.
The global Europium Nanoparticle for Rapid Diagnosis market is currently a relatively small but high-value-added segment of the upstream in-vitro diagnostics materials industry. Demand mainly comes from manufacturers of fluorescence immunochromatographic and POCT reagents. Compared with conventional colloidal gold labels, europium nanoparticles offer advantages in detection sensitivity, quantitative measurement capability, and signal stability, supporting their increasing adoption in rapid tests for infectious diseases, cardiovascular biomarkers, inflammatory markers, hormones, and other biomarkers. The supplier base primarily consists of specialized fluorescent microsphere/nanoparticle manufacturers, life-science material companies, and selected IVD raw-material suppliers. As POCT continues to shift from qualitative testing toward highly sensitive quantitative detection and time-resolved fluorescence and fluorescence immunochromatographic technologies gain wider adoption, demand for europium nanoparticles for rapid diagnosis is expected to continue growing.
Report Scope
This report is a detailed and comprehensive analysis for global Europium Nanoparticle for Rapid Diagnosis market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Europium Nanoparticle for Rapid Diagnosis market size and forecasts, in consumption value ($ Million), sales quantity (Kilotons), and average selling prices (US$/Ton), 2021-2032
Global Europium Nanoparticle for Rapid Diagnosis market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Kilotons), and average selling prices (US$/Ton), 2021-2032
Global Europium Nanoparticle for Rapid Diagnosis market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Kilotons), and average selling prices (US$/Ton), 2021-2032
Global Europium Nanoparticle for Rapid Diagnosis market shares of main players, shipments in revenue ($ Million), sales quantity (Kilotons), and ASP (US$/Ton), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Europium Nanoparticle for Rapid Diagnosis
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Europium Nanoparticle for Rapid Diagnosis market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Thermo Fisher Scientific, Merck, Bangs Laboratories, Inc., Suzhou NanoMicro Technology Co, Polysciences Inc, CD Bioparticles, Hangzhou Bioeast Biotech Co, Nanjing Microoetection, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Europium Nanoparticle for Rapid Diagnosis market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
300 nm
200 nm
100 nm
Other
Market segment by Material Structure
Europium-Doped Nanoparticles
Europium Chelate Nanoparticles
Europium Coordination Polymer Nanoparticles
Others
Market segment by Surface Functionalization
Carboxyl-Functionalized
Amino-Functionalized
Streptavidin-Functionalized
Other Functionalization
Market segment by Application
Tumor Marker Testing
Thyroid Function Testing
Sex Hormone Testing
Infectious Disease Testing
Cardiovascular and Cardiac Biomarkers Testing
Other
Major players covered
Thermo Fisher Scientific
Merck
Bangs Laboratories, Inc.
Suzhou NanoMicro Technology Co
Polysciences Inc
CD Bioparticles
Hangzhou Bioeast Biotech Co
Nanjing Microoetection
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Europium Nanoparticle for Rapid Diagnosis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Europium Nanoparticle for Rapid Diagnosis, with price, sales quantity, revenue, and global market share of Europium Nanoparticle for Rapid Diagnosis from 2021 to 2026.
Chapter 3, the Europium Nanoparticle for Rapid Diagnosis competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Europium Nanoparticle for Rapid Diagnosis breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Europium Nanoparticle for Rapid Diagnosis market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Europium Nanoparticle for Rapid Diagnosis.
Chapter 14 and 15, to describe Europium Nanoparticle for Rapid Diagnosis sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Thermo Fisher Scientific
Merck
Bangs Laboratories, Inc.
Suzhou NanoMicro Technology Co
Polysciences Inc
CD Bioparticles
Hangzhou Bioeast Biotech Co
Nanjing Microoetection. Industry analysis & Market Report on Thermo Fisher Scientific
Merck
Bangs Laboratories, Inc.
Suzhou NanoMicro Technology Co
Polysciences Inc
CD Bioparticles
Hangzhou Bioeast Biotech Co
Nanjing Microoetection is a syndicated market report, published as Global Europium Nanoparticle for Rapid Diagnosis Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Thermo Fisher Scientific
Merck
Bangs Laboratories, Inc.
Suzhou NanoMicro Technology Co
Polysciences Inc
CD Bioparticles
Hangzhou Bioeast Biotech Co
Nanjing Microoetection market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.